THERAPY DOSSIER · th-089dbf3a4ab7

Parstatin (41-mer peptide from protease-activated receptor 1 cleavage)

Biologic · Biologic (parstatin peptide from PAR1), preclinical; no matching trial identified

Evidence & regulatory context

Mechanism: Biologic (parstatin peptide from PAR1), preclinical; no matching trial identified
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22965158 ↗2012Reported benefit

Parstatin prevents renal injury following ischemia/reperfusion and radiocontrast administration.

MixedIschaemia-reperfusionRenalWistar (rats)MaleSystemic administration15 min before or immediately after renal ischaemia; single dose before inductio…

Model: Bilateral occlusion of renal arteries and veins for 45 min followed by 4 h reperfusion in rats, and intravenous iopromide radiocontrast in rabbits

Parstatin attenuated renal dysfunction and histological injury in both models in a dose-dependent manner, with more prominent protection of tubular than glomerular function.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…